Entasis Therapeutics Holdings Inc. (ETTX): 0 Analysts rated it as Sell ETTX


Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) changes shares on Tuesday trading session, with a change of 4.61% or $0.13 shares. The trading starts at $2.82 and closed at $2.82 throughout the day. The trading session low price was $2.82 and day high was $2.98 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 96709.0 while its average volume is 187.43K. In other hand, the ETTX market cap reached to $86.49M.

On July 6, 2020, BRIEF-Entasis Therapeutics Awarded Contract From National Institutes Of Health. According to the news reported on Reuters, * ENTASIS THERAPEUTICS AWARDED CONTRACT FROM NATIONAL INSTITUTES OF HEALTH

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.59% and up 5.36% for month. Its quarterly performance was 7.28% above, while its half year performance is down -42.08%. ETTX yearly performance stood at negative -54.19% and fall -40.64% for year-to-date. Current recommendation for Entasis Therapeutics Holdings Inc. is 1.80.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. ETTX EPS (TTM) for 12-month is -3.49. EPS for this year is -3.50%, while for the next year its value is -1.48. Its EPS Q/Q reached -16.50%.

Let’s take a look on the analyst recommendations on ETTX for the current month and previous month. For the current month, 5 of 5 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $5.00 – $9.00. Average target price for ETTX was reached at $6.80.

Novo Holdings A/S, Blackstone Group Inc. and Sofinnova Investments, Inc. are the top three holders in Entasis Therapeutics Holdings Inc. (ETTX) stock. On Mar 30, 2020, Novo Holdings A/S has 2.18 million shares which valued 5.77 million. On Mar 30, 2020, Blackstone Group Inc. owned 1.62 million shares which valued at 4.29 million. On Mar 30, 2020, Sofinnova Investments, Inc. has a total of 1.18 million shares which valued at 3.12 million. In the end, Sofinnova Investments, Inc. have 8.08% shares outstanding of Entasis Therapeutics Holdings Inc. (ETTX) on Mar 30, 2020. The insider ownership moved to 51.30% and institutional holding shifted to 33.90%.

The company posted an EPS (TTM) of -3.49. According to the most recent quarter report on (Jun 2020), 5 analysts estimated an average EPS of -0.74, while -1.02 EPS posted a year ago period. Analyst Estimated EPS for ETTX published in the report was -$1.02 – -$0.39 during the same period. Comparing with last year, the average estimated EPS was -1.02 which is higher than -1.15 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for ETTX fall -26.25% for period of 200 days. SMA for 50 days was -0.29% which is showing red signal, while SMA-20 was -5.56%. The moving average value for Entasis Therapeutics Holdings Inc. (ETTX) is 24.12k and 0.60% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in ETTX stock. On Jun 11, Innoviva, Inc., 10% Owner, bought 12,677,490 trading shares at the cost of $2.50, which valued at 31.69 million.